Viatris | VTRS - Gross Profit On Sales

Stock Price
13.25
Daily Change
-0.25 -1.85%
Monthly
-16.77%
Yearly
40.36%
Q1 Forecast
13.10

Viatris reported $1.15B in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Celltrion KRW 626.11B 81.75B Sep/2025
Cspc Pharmaceutical CNY 4.34B 333.68M Sep/2025
Deva Holding AS TRY 1.32B 235.77M Sep/2023
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Organigram Holdings CAD 23.32M 8.52M Dec/2025
Pharma Mar EUR 86.7M 53.34M Dec/2025
Qiagen NV USD 325.27M 19.53M Dec/2025
Sartorius EUR 393.2M 23M Sep/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.15B 223.6M Dec/2025
Zealand Pharma A/S 68.91M 19.35M Dec/2025
Zz Pientze Pharmaceu CNY 296.13M 1.1B Jun/2025